Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-12-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00588-08PMID 19104028PMCID PMC2650521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oseltamivir

  2012cited by this paper
• Update on avian influenza A (H5N1) virus infection in humans

  2009cited by this paper
• Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein

  2008cited by this paper
• P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier

  2008cited by this paper
• Update on avian influenza A (H5N1) virus infection in humans.

  2008cited by this paper
• Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

  2008cited by this paper
• Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid

  2008cited by this paper
• Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.

  2008cited by this paper
• Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites.

  2008cited by this paper
• Neuroexcitatory actions of Tamiflu and its carboxylate metabolite.

  2007cited by this paper
• A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination

  2007cited by this paper
• Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects

  2007cited by this paper
• Importance of Collection Tube during Clinical Studies of Oseltamivir

  2007cited by this paper
• Writing Committee of the Second World Health Organization (WHO) Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus

  2007cited by this paper
• Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus

  2007cited by this paper
• Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine.

  2007cited by this paper
• Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2

  2007cited by this paper
• Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

  2006cited by this paper
• Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases

  2006cited by this paper
• Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel

  2006cited by this paper
• Oseltamivir Resistance During Treatment of Influenza A (H5N1) Infection

  2006cited by this paper
• The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.

  2006cited by this paper
• Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects

  2006cited by this paper
• Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.

  2005cited by this paper
• Oseltamivir resistance during treatment of influenza A (H5N1) infection.

  2005influential reference
• Immuno-histochemical detection of MRPs in human lung cells in culture.

  2005cited by this paper
• Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

  2005cited by this paper
• Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.

  2004cited by this paper
• Impact of Drug Transporter Studies on Drug Discovery and Development

  2003cited by this paper
• Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

  2003cited by this paper
• Early administration of oral oseltamivir increases the benefits of influenza treatment.

  2003cited by this paper
• Expression of ATP-binding cassette transporter in human salivary ducts.

  2003cited by this paper
• The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

  2002cited by this paper
• Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children

  2001cited by this paper
• Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

  2000cited by this paper
• Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

  2000cited by this paper
• USE OF THE SELECTIVE ORAL NEURAMINIDASE INHIBITOR OSELTAMIVIR TO PREVENT INFLUENZA

  2000cited by this paper
• Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

  2000cited by this paper
• Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.

  1999cited by this paper
• Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

  1999cited by this paper
• Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802

  1999cited by this paper
• Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104

  1997cited by this paper
• Mechanisms mediating renal secretion of organic anions and cations.

  1993cited by this paper
• Rational design of potent sialidase-based inhibitors of influenza virus replication

  1993cited by this paper

• Bioequivalence and Safety of Two Oseltamivir Phosphate for Oral Suspension in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study

  2025cites this paper
• Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system

  2025cites this paper
• Pharmacologic background and clinical issue of anti-influenza drugs

  2024cites this paper
• Considerations when treating influenza infections with oseltamivir

  2024cites this paper
• Special Section on New Era of Transporter Science — Minireview Emerging Roles of the Human Solute Carrier 22 Family S

  2022cites this paper
• Inverse optimal control for positive impulsive systems toward personalized therapeutic regimens

  2022cites this paper
• Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation.

  2022cites this paper
• Pannexin-1 channel opening is critical for COVID-19 pathogenesis

  2021cites this paper
• Emerging Roles of the Human Solute Carrier 22 Family

  2021cites this paper
• Passivity-Based Inverse Optimal Impulsive Control for Influenza Treatment in the Host

  2020cites this paper
• PK/PD-Based Impulsive Control to Tailor Therapies in Infectious Diseases

  2020cites this paper
• Oseltamivir - Current dosing recommendations reduce the therapeutic benefit in patients with mild to moderate renal function and/or large body mass. A review of the literature with recommendations to optimize dosing, including the use of therapeutic drug monitoring.

  2020cites this paper
• Efficacy and mechanism of actions of natural antimicrobial drugs.

  2020cites this paper
• Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.

  2020cites this paper
• Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs’ excretion into the bile and kidney

  2020cites this paper
• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

  2020cites this paper
• Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

  2020cites this paper
• ANTIVIRAL DRUGS FOR INFLUENZA VIRUSES

  2019cites this paper
• Learning neural impulsive MPC for tailoring therapies in viral infections

  2019cites this paper
• Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population

  2019cites this paper
• Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities

  2019cites this paper
• Neuraminidase Inhibitors in Influenza Treatment and Prevention–Is It Time to Call It a Day?

  2018cites this paper
• Neuraminidase inhibitors — is it time to call it a day?

  2018cites this paper
• Impulsive MPC for Influenza Infection Treatment at Variable Time

  2018cites this paper
• Prescription – Pollution – Poo – Pandemics - Priorities : Neuraminidase Inhibitors from an Environmental Resistance Development Perspective

  2018cites this paper
• PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.

  2018cites this paper
• ANTIVIRAL DRUG REVIEW A GUIDE TO CLINICIANS

  2017cites this paper
• Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report

  2017cites this paper
• Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population

  2017cites this paper
• Prospective Surveillance of Antiviral Resistance in Hospitalized Infants Less than 12 Months of Age with A(H3N2) Influenza Infection and Treated with Oseltamivir

  2017cites this paper
• Pharmacogenetics of carboxylesterase 1

  2017cites this paper
• Inverse Optimal Impulsive Control Based Treatment of Influenza Infection

  2017cites this paper
• Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants

  2017cites this paper
• Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers

  2016cites this paper
• Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy

  2016cites this paper
• The mechanisms of sudden‐onset type adverse reactions to oseltamivir

  2016cites this paper
• Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms

  2016cites this paper
• Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection

  2016influential citation
• Therapeutic drug monitoring of anti-infective agents in critically ill patients

  2016cites this paper
• Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.

  2016cites this paper
• Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility

  2016cites this paper
• Tamiflu in the Water : Resistance Dynamics of Influenza A Virus in Mallards Exposed to Oseltamivir

  2016cites this paper
• Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates

  2015cites this paper
• Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.

  2015cites this paper
• Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design

  2015cites this paper
• Effects of Alcohol on Human Carboxylesterase Drug Metabolism

  2015cites this paper
• Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.

  2015cites this paper
• Optimizing antiviral therapy for influenza: understanding the evidence

  2015cites this paper
• Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study

  2014cites this paper
• Oseltamivir Dosing in Critically Ill Patients With Severe Influenza

  2014cites this paper
• Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition

  2014influential citation
• Correction: Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study

  2014cites this paper
• A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling

  2014cites this paper
• Antiviral combinations for severe influenza

  2014cites this paper
• Hospitalized with Influenza A and B infections

  2013cites this paper
• I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses

  2013cites this paper
• Antivirals: Targets and use

  2013cites this paper
• DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation

  2013cites this paper
• Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance

  2013cites this paper
• Comparison of Oseltamivir and Oseltamivir Carboxylate Concentrations in Venous Plasma, Venous Blood, and Capillary Blood in Healthy Volunteers

  2013cites this paper
• Pharmacokinetic Properties ofAnti‐Influenza Neuraminidase Inhibitors

  2013cites this paper
• Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects

  2013cites this paper
• Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility

  2013cites this paper
• Oseltamivir in neonates, infants and young children: a focus on clinical pharmacology.

  2013cites this paper
• A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

  2013cites this paper
• Clinical Practice Guideline for Antiviral Treatment and Chemoprophylaxis of Seasonal Influenza

  2012cites this paper
• Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy

  2012cites this paper
• Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model.

  2012cites this paper
• Diagnosis, management and outcomes of adults hospitalized with influenza.

  2012cites this paper
• Clinical Experience with Influenza Virus Sialidase Inhibitors

  2012cites this paper
• Role of Phase I Metabolism in Drug Activation and Clinical Treatment Outcomes

  2012cites this paper
• Oseltamivir in Seasonal , Avian H 5 N 1 and Pandemic 2009 A / H 1 N 1 Influenza Pharmacokinetic and Pharmacodynamic Characteristics

  2012influential citation
• The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics

  2012cites this paper
• Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza

  2012cites this paper
• Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation

  2012cites this paper
• Pharmacologic Considerations for Oseltamivir Disposition

  2011cites this paper
• Pharmacokinetics and Diffusion into Sputum of Oseltamivir and Oseltamivir Carboxylate in Adults with Cystic Fibrosis

  2011cites this paper
• Antiviral management of Influenza A (H1N1) in critical care.

  2011cites this paper
• An Open-Label Crossover Study To Evaluate Potential Pharmacokinetic Interactions between Oral Oseltamivir and Intravenous Zanamivir in Healthy Thai Adults

  2011cites this paper
• Oseltamivir pharmacokinetics in pregnancy: a commentary.

  2011cites this paper
• UvA-DARE ( Digital Academic Repository ) Laboratory Capacity Building in Asia for Infectious Disease Research : Experiences from the South East Asia Infectious Disease Clinical Research Network ( SEAICRN )

  2010cites this paper
• Oseltamivir dosing in children undergoing hemodialysis.

  2010cites this paper
• Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza

  2010cites this paper
• Oseltamivir in human avian influenza infection

  2010cites this paper
• [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

  2010cites this paper
• Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza

  2010cites this paper
• Safety and pharmacokinetics of oseltamivir at standard and high dosages.

  2010cites this paper
• Laboratory Capacity Building in Asia for Infectious Disease Research: Experiences from the South East Asia Infectious Disease Clinical Research Network (SEAICRN)

  2010cites this paper
• Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia

  2010cites this paper
• Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis

  2010cites this paper
• Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

  2010cites this paper
• A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza.

  2010cites this paper
• Antiviral Drugs (Other than Antiretrovirals)

  2010cites this paper
• Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses†

  2010cites this paper
• Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.

  2010cites this paper
• Oseltamivir Dosing in Children Undergoing Hemodialysis

  2010cites this paper
• Novel swine-origin influenza A virus in humans: another pandemic knocking at the door

  2009cites this paper
• What Is the Optimal Therapy for Patients with H5N1 Influenza?

  2009cites this paper
• An influenza A H1N1 virus revival – pandemic H1N1/09 virus

  2009cites this paper
• Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System

  2009cites this paper